5-Hydroxymethylcytosine (5hmC) is a critical marker in the study of dynamic epigenetic shifts, marking an initial phase in the DNA demethylation process. Its altered distribution in various cancers earmarks it as a valuable biomarker for disease detection and monitoring. The slow integration of 5hmC as a biomarker is primarily due to the high costs and complexity of current analysis methods, which are significant hurdles for its broad application. The lack of a method that can accurately and affordably map 5hmC in tumor or blood samples—where it has the most significant potential for clinical use yet presents the lowest levels—intensifies this challenge.
Our project is designed to overcome this obstacle by developing a specialized DNA microarray for 5hmC analysis. Utilizing a patented process for the direct fluorescent labeling of 5hmC in conjunction with commercially available microarrays, our goal is to generate detailed maps of 5hmC distribution in both healthy and disease states.
The initial phase of our experiment utilized a high-content custom microarray to investigate 5hmC at ~60,000 genomic sites with a potential epigenetic variation. The presence of 5hmC in a particular DNA sequence is reflected by varying fluorescence intensities across the array’s spots. The disparity in 5hmC distribution between healthy and diseased states acts as a biomarker for illness, and only the differential 5hmC loci will be featured on a condensed microarray, enabling disease identification at a significantly lower cost. Due to budgetary constraints, our proof of concept was limited to 30 samples. We initially planned to examine 10 samples each from Acute Myeloid Leukemia (AML), Follicular Lymphoma (FL), and healthy controls. However, upon commencing the experiment, we realized that a sample size of 10 for each condition would be insufficient and thus decided to concentrate on comparing AML with healthy controls, analyzing 15 samples from each group.
The anticipated impact of our project is not confined to scientific progress alone. By creating an economical platform for 5hmC analysis, we aim to democratize advanced diagnostic methods. This innovation has the potential to refine biomarker identification, inform personalized treatment choices, and ultimately enhance patient care. Our project is committed to bridging the gap between pioneering research and clinical practice, offering a tangible solution with significant implications for the future of healthcare.
